» Articles » PMID: 21349997

DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death Following Radiotherapy

Abstract

Purpose: Radiotherapy plays an integral role in the treatment of head and neck squamous cell carcinoma (HNSCC). Although proteins involved in DNA repair may predict HNSCC response to radiotherapy, none has been validated in this context. We examined whether differential expression of double-strand DNA break (DSB) repair proteins in HNSCC, the chief mediators of DNA repair following irradiation, predict for treatment outcomes.

Experimental Design: Archival HNSCC tumor specimens (n = 89) were assembled onto a tissue microarray and stained with antibodies raised against 38 biomarkers. The biomarker set was enriched for proteins involved in DSB repair, in addition to established mechanistic markers of radioresistance. Staining was correlated with treatment response and survival alongside established clinical and pathologic covariates. Results were validated in an independent intramural cohort (n = 34).

Results: Ku80, a key mediator of DSB repair, correlated most closely with clinical outcomes. Ku80 was overexpressed in half of all tumors, and its expression was independent of all other covariates examined. Ku80 overexpression was an independent predictor for both locoregional failure and mortality following radiotherapy (P < 0.01). The predictive power of Ku80 overexpression was confined largely to HPV-negative HNSCC, where it conferred a nine-fold greater risk of death at two years.

Conclusions: Ku80 overexpression is a common feature of HNSCC, and is a candidate DNA repair-related biomarker for radiation treatment failure and death, particularly in patients with high-risk HPV-negative disease. It is a promising, mechanistically rational biomarker to select individual HPV-negative HNSCC patients for strategies to intensify treatment.

Citing Articles

Tissue microarray analyses of the essential DNA repair factors ATM, DNA-PKcs and Ku80 in head and neck squamous cell carcinoma.

Zech H, von Bargen C, Oetting A, Mockelmann N, Moller-Koop C, Witt M Radiat Oncol. 2024; 19(1):150.

PMID: 39478631 PMC: 11523811. DOI: 10.1186/s13014-024-02541-3.


Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review).

Yongprayoon V, Wattanakul N, Khomate W, Apithanangsiri N, Kasitipradit T, Nantajit D Oncol Rep. 2024; 51(6).

PMID: 38606512 PMC: 11040537. DOI: 10.3892/or.2024.8733.


DNA Double-Strand Break Response and Repair Gene Polymorphisms May Influence Therapy Results and Prognosis in Head and Neck Cancer Patients.

Butkiewicz D, Krzesniak M, Gdowicz-Klosok A, Skladowski K, Rutkowski T Cancers (Basel). 2023; 15(20).

PMID: 37894339 PMC: 10605140. DOI: 10.3390/cancers15204972.


Suppression of Long Noncoding RNA SNHG1 Inhibits the Development of Hypopharyngeal Squamous Cell Carcinoma via Increasing PARP6 Expression.

Chen Q, He X, Li B, Chen J, Tang X Evid Based Complement Alternat Med. 2022; 2022:1562219.

PMID: 35836822 PMC: 9276473. DOI: 10.1155/2022/1562219.


Evaluation of the Response of HNSCC Cell Lines to γ-Rays and C Ions: Can Radioresistant Tumors Be Identified and Selected for C Ion Radiotherapy?.

Ding L, Sishc B, Polsdofer E, Yordy J, Facoetti A, Ciocca M Front Oncol. 2022; 12:812961.

PMID: 35280731 PMC: 8914432. DOI: 10.3389/fonc.2022.812961.


References
1.
Chang H, Kim S, Yi S, Son S, Song D, Moon S . Expression of Ku80 correlates with sensitivities to radiation in cancer cell lines of the head and neck. Oral Oncol. 2006; 42(10):979-86. DOI: 10.1016/j.oraloncology.2005.12.016. View

2.
Matsuoka S, Ballif B, Smogorzewska A, McDonald 3rd E, Hurov K, Luo J . ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007; 316(5828):1160-6. DOI: 10.1126/science.1140321. View

3.
Mahaney B, Meek K, Lees-Miller S . Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J. 2009; 417(3):639-50. PMC: 2975036. DOI: 10.1042/BJ20080413. View

4.
Fong P, Boss D, Yap T, Tutt A, Wu P, Mergui-Roelvink M . Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2):123-34. DOI: 10.1056/NEJMoa0900212. View

5.
Bryant H, Schultz N, Thomas H, Parker K, Flower D, Lopez E . Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-7. DOI: 10.1038/nature03443. View